| |
|
|
|
|
|
|
|||
|
Blood, 21 May 2009, Vol. 113, No. 21, pp. 5041-5048. Prepublished online as a Blood First Edition Paper on September 22, 2008; DOI 10.1182/blood-2008-07-171678.
PLENARY PAPER HapMap scanning of novel human minor histocompatibility antigens![]() ![]() 1 Division of Immunology, Aichi Cancer Center Research Institute, Nagoya, Japan; 2 Department of Pediatrics and Neonatology, Nagoya City University, Graduate School of Medical Science, Nagoya, Japan; 3 Department of Hematology/Oncology and 4 The 21st Century Center of Excellence (COE) Program, Graduate School of Medicine, University of Tokyo, Tokyo, Japan; 5 Core Research for Evolutional Science and Technology, Japan Science and Technology Agency, Saitama, Japan; 6 Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Japan; 7 Department of Information and Communication Engineering, Graduate School of Information Science, University of Tokyo, Tokyo, Japan; 8 Department of Hematology, Japanese Red Cross Nagoya First Hospital, Nagoya, Japan; 9 Department of Pediatrics, Higashi Municipal Hospital of Nagoya, Nagoya, Japan; 10 Department of Infectious Diseases, Hamamatsu University School of Medicine, Hamamatsu, Japan; 11 Program in Immunology, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA; 12 Department of Hematology and Cell Therapy, Aichi Cancer Center Central Hospital, Nagoya, Japan; and 13 Aichi Comprehensive Health Science Center, Aichi Health Promotion Foundation, Chita-gun, Japan
Minor histocompatibility antigens (mHags) are molecular targets of allo-immunity associated with hematopoietic stem cell transplantation (HSCT) and involved in graft-versus-host disease, but they also have beneficial antitumor activity. mHags are typically defined by host SNPs that are not shared by the donor and are immunologically recognized by cytotoxic T cells isolated from post-HSCT patients. However, the number of molecularly identified mHags is still too small to allow prospective studies of their clinical importance in transplantation medicine, mostly due to the lack of an efficient method for isolation. Here we show that when combined with conventional immunologic assays, the large data set from the International HapMap Project can be directly used for genetic mapping of novel mHags. Based on the immunologically determined mHag status in HapMap panels, a target mHag locus can be uniquely mapped through whole genome association scanning taking advantage of the unprecedented resolution and power obtained with more than 3 000 000 markers. The feasibility of our approach could be supported by extensive simulations and further confirmed by actually isolating 2 novel mHags as well as 1 previously identified example. The HapMap data set represents an invaluable resource for investigating human variation, with obvious applications in genetic mapping of clinically relevant human traits.
Related Article in Blood Online:
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Copyright © 2009 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||